Table 1.

Study characteristics

Author [ref].	Study type	Drug studied	Drug dosage per day	Nerve injury diagnosis	Participants		Age in years		Women
					Gabapentinoids	Placebo	Gabapentinoids	Placebo	Gabapentinoids	Placebo
Markman et al. [21]	RCT	Pregabalin	150 mg to 600 mg	Mostly subjective criteriaa	51 (275)	49 (267)	53 ± 13	54 ± 13	NR	NR
van Seventer et al. [33]	RCT	Pregabalin	150 mg to 600 mg	Subjective criteria	50 (127)	50 (127)	52 ± 14	51 ± 13	61 (77)	41 (52)
Gordh et al. [10]	Quasi-RCT: crossoverb	Gabapentin	300 mg to 2400 mg	Subjective criteria	100 (98)	100 (98)	49 ± NR	49 ± NR	53 (52)	53 (52)
Jenkins et al. [13]	Quasi-RCT: crossoverb	Pregabalin	300 mg	Subjective criteria	100 (25)	100 (25)	50 ± 14	50 ± 14	56 (14)	56 (14)

Data presented as % (n) or mean ± SD. NR = not reported.

^aMostly subjective because nerve conduction studies confirming neuropathy were optional.

^bPatients were randomized to receive either gabapentinoids or placebo in the first period, followed by a washout period, then switched to the alternate treatment in the second period.